Atlas Trials

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

Clinical trial NCT05016349 · UNKNOWN

Trial details

NCT number
NCT05016349
Sponsor
Mahmoud Ramadan mohamed Elkazzaz
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer Female
Start date
2021-08-01
Primary completion
2021-10-01
Enrollment
160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.